Navigation Links
Anthera Pharmaceuticals Reports 2011 First Quarter Financial Results and Operational Update
Date:5/3/2011

Clinical

  • Enrollment and site initiations continue according to the Company's estimated timelines in the PEARL-SC study.  Active enrollment is underway in the following countries: United States, Mexico, Peru, Chile, the Philippines, Argentina and Colombia. PEARL-SC is examining the therapeutic benefit of A-623, which utilizes a subcutaneous formulation and modulates both soluble and membrane-bound BAFF in patients with systemic lupus erythematosus (lupus). The primary endpoint of the PEARL-SC study is an SLE responder index (SRI). Details regarding the study can be found at http://www.clinicaltrials.gov/ct2/show/NCT01162681.
  • The PEARL-SC open label extension protocol has been submitted to FDA. This would allow Anthera to capture important long term safety data and optimize enrollment by giving study subjects an option to continue participation on active therapy beyond the PEARL-SC duration.
  • In the Phase 3 VISTA-16 study, enrollment surpassed the 1000 patient threshold during the first quarter, triggering a pre-defined, blinded biomarker analysis conducted by an independent statistician. The statistician examined four predefined biomarkers of cardiovascular risk and one composite responder index including sPLA2, IL-6, CRP, LDL-C and a composite analysis comparing the proportion of patients achieving an LDL-C < 70 and a CRP < 1. Subsequent to the end of the first quarter, the Company announced a favorable outcome from the biomarker analysis. The VISTA-16 clinical study is designed to reduce inflammation and the risk of subsequent secondary Major Adverse Cardiovascular Events (MACE) in high-risk patients following an ACS. Details regarding the study can be found at http://www.clinicaltrials.gov/ct2/show/NCT01130246. The next substantial review of clinical safety and efficacy data is planned once 50
    '/>"/>

  • SOURCE Anthera Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl
    2. Anthera Announces Conference Call to Discuss Analytical Method and Timing of Upcoming VISTA-16 Biomarker Analysis
    3. Anthera Pharmaceuticals Names Lawrence Rosania as Vice President of Global Regulatory Affairs and Compliance
    4. Dr. Peter Thompson Joins Anthera Pharmaceuticals Board of Directors
    5. Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Antheras Investigational Novel Peptibody Agent
    6. Anthera Announces Update Call Regarding Vial Problems
    7. Anthera Pharmaceuticals Reports 2010 Third Quarter Financial Results and Operational Update
    8. Anthera Announces Third Quarter 2010 Financial Report and Conference Call
    9. Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing
    10. Anthera Pharmaceuticals to Present at Deutsche Bank Securities 35th Annual Health Care Conference
    11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... PHILADELPHIA , Dec. 23, 2014 ... a medical device company focused on skin permeation, ... that Scott W. Hollander has been ... Mr. Hollander has more than 20 years of ... equipment industries, and most recently served as Vice ...
    (Date:12/24/2014)... 23, 2014 ResMed (NYSE: RMD ) ... against Chinese medical device manufacturer BMC Medical Co., Ltd. ... BMC,s masks listed below infringe ResMed,s patents, and entered an ... in the United States : ... , Willow nasal pillows mask , iVolve full ...
    (Date:12/24/2014)... 2014   Synageva BioPharma Corp. (NASDAQ: ... therapeutic products for rare disorders, today announced validation ... Marketing Authorization Application (MAA) for sebelipase alfa for ... request for accelerated assessment, which has the potential ... The MAA, and the Biologics License ...
    Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
    ... from Mayo ClinicROCHESTER, Minn., March 23 Here ... Edge, Mayo Clinic,s research magazine. You may cite ... you wish. Reprinting is allowed with proper attribution. ... editorial policies permit: Visit http://discoverysedge.mayo.edu for ...
    ... Since 1993, when the PLCO trial was started, we have ... have others. The initial report of the results of this ... published last week in the New England Journal of Medicine ... The studies offer conflicting evidence about the possibility of a ...
    Cached Medicine Technology:Discovery's Edge Spring Issue - http://discoverysedge.mayo.edu 2A Joint Statement From America's Prostate Cancer Advocacy, Education, and Support Organizations 2A Joint Statement From America's Prostate Cancer Advocacy, Education, and Support Organizations 3
    (Date:12/25/2014)... “Every three months the trends for ... evening dress will be one of the hottest styles in ... says. Today, the company releases 26 A-line sweetheart evening dresses, ... off. , “We are trying our best to help ... latest designs. Along with affordable prices, we provide discounted delivery ...
    (Date:12/25/2014)... Los Angeles, CA (PRWEB) December 25, 2014 ... Blaise Dolcemaschio was created in honor of a true ... premiere at two film festivals including the 24 hours of ... Film Festival in Bangladesh. , Actress, screenwriter and ... and helped produce this film together with her husband, ...
    (Date:12/25/2014)... Helen Harris’ RP (Retinitis Pigmentosa) International founder ... an 8 year battle with breast cancer. , ... her home in Woodland Hills California after an 8 ... , As the founder and volunteer President of ... championed many of today's greatest breakthroughs in restoring and ...
    (Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... children with complex chronic illnesses can receive effective, less expensive ... with easy access to a team of dedicated health care ... to become seriously ill and need either hospitalization or a ... an enhanced medical home clinic at the University of Texas ...
    (Date:12/25/2014)... -- Among early stage breast cancer patients who undergo ... percent will eventually develop leukemia as a result of ... comes from a review of more than 20,000 breast ... suggests that the risk for developing treatment-related leukemia, though ... "The frequency of bone marrow cancers such as ...
    Breaking Medicine News(10 mins):Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
    ... CST-Arwin will represent the complete AC and DC line of axial ... more than 100 axial fans ranging in size from 25mm to ... ... -- NMB Technologies Corporation, a Minebea Group Company, and CST-Arwin, a ...
    ... WASHINGTON, DC, November 3, 2008 Parents are surprisingly ... visit to their child,s pediatrician, including those who have ... would look to their pediatrician for a referral, according ... the journal Pediatrics . , "This is a ...
    ... 3, 2008) Influenza vaccination rates for adolescents who suffer ... low, according to a recent study. , ... Pediatrics, was based at the Department of ... Harvard Pilgrim Health Care. , "Influenza vaccination has been ...
    ... RAMSEY, N.J., Nov. 3 Konica Minolta ... the industrial measurement of color,light and shape, ... Analysis Software.,This new software product used in ... accurate measurement of skin,color simultaneously with a ...
    ... two-pronged attack, a novel designer molecule fights malignant melanoma. It ... led by the University of Bonn. On the one hand, ... this way alerts the immune system. The body,s own defences ... the same time, the novel molecule also puts pressure on ...
    ... to Ask Voters ... of Health Care, TRENTON, N.J., Nov. 1 Calling themselves ... forces to ask the state,s public policy makers to put health ... level. The First Ladies,joined the newest members of the Partnership to ...
    Cached Medicine News:Health News:NMB's Fans and Blowers to be Represented in Canada by CST-Arwin 2Health News:Parents comfortable with alcohol screening in pediatricians' offices 2Health News:Parents comfortable with alcohol screening in pediatricians' offices 3Health News:Flu vaccination rates lag for at-risk adolescents 2Health News:Konica Minolta Sensing Americas Announces the Launch of the CM-SA Skin Analysis Software 2Health News:Substance tackles skin cancer from 2 sides 2Health News:On Weekend Before the Election, New Jersey's First Ladies Speak Out for Healthcare 2Health News:On Weekend Before the Election, New Jersey's First Ladies Speak Out for Healthcare 3
    Microalbumin Linearity Control...
    Total IgE Control...
    The K-ASSAY Lipid Controls are assayed controls produced from fresh human sera to monitor the accuracy and precision of quantitative lipid determinations of human sera specimens....
    The K-ASSAY hs-CRP Control Set is intended to be used as a consistent test sample of known concentrations for monitoring the performance of hs-CRP (high sensitive C-Reactive Protein) immunoturbimetri...
    Medicine Products: